Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by WealthBridge Investment Counsel Inc.

WealthBridge Investment Counsel Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 74,055 shares of the biopharmaceutical company’s stock after selling 3,250 shares during the period. Gilead Sciences accounts for about 2.0% of WealthBridge Investment Counsel Inc.’s portfolio, making the stock its 28th largest holding. WealthBridge Investment Counsel Inc.’s holdings in Gilead Sciences were worth $5,425,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in GILD. Altfest L J & Co. Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $210,000. Federated Hermes Inc. boosted its holdings in Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after purchasing an additional 175,925 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Gilead Sciences by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock worth $589,873,000 after purchasing an additional 87,482 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in Gilead Sciences during the 4th quarter worth about $74,000. Finally, Eagle Asset Management Inc. raised its position in Gilead Sciences by 23.6% in the 4th quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock valued at $25,724,000 after purchasing an additional 60,697 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

GILD traded down $1.81 on Thursday, hitting $66.59. 3,995,673 shares of the company traded hands, compared to its average volume of 8,998,495. The company has a 50 day moving average of $66.03 and a 200-day moving average of $72.29. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $87.86. The stock has a market capitalization of $82.96 billion, a PE ratio of 184.97, a PEG ratio of 2.91 and a beta of 0.18. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period last year, the company earned $1.37 earnings per share. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.63%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on GILD shares. TD Cowen cut their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Royal Bank of Canada restated a “sector perform” rating and issued a $74.00 price objective on shares of Gilead Sciences in a report on Monday. Barclays decreased their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. UBS Group cut their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Thursday, June 20th. Twelve analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $83.47.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.